tetano
Editor, Senior Moderator
New Microbes New Infect. 2020 Mar 31;35:100672. doi: 10.1016/j.nmni.2020.100672. eCollection 2020 May.
Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view.
Abduljalil JM[SUP]1[/SUP], Abduljalil BM[SUP]2[/SUP].
Author information
Abstract
Since the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, the number of globally confirmed cases according to World Health Organization statistics reached 292 124 in 189 countries by 22 March 2020. The number of deaths reached 12 784, with estimated case-fatality rates ranging from 0.5% to 5.7%. Children population seems to be the least affected by the disease, while the highest rate of death is among the elderly and people with comorbidities. Most infected individuals are asymptomatic or only exhibit mild symptoms. After the incubation period, the most common symptoms are fever, cough and fatigue. Asymptomatic carrier state is of paramount importance because of carriers' ability to spread the infection and to shed the virus into the air and surroundings. Although much is still unknown about SARS-CoV-2, the scientific research is moving at an unprecedented pace towards understanding the nature, effective control, prevention and treatment of SARS-CoV-2. Various reports have suggested an in vivo evolution of the virus, which may explain the rapid spread and changing epidemiology of SARS-CoV-2, but further evidence is needed. Unfortunately, no effective treatment or therapeutic drug is available for the disease; only supportive treatment and classical intervention measures are available for confronting the SARS-CoV-2 pandemic.
? 2020 The Author(s).
KEYWORDS:
2109-nCoV; Asymptomatic; COVID-19; Coronavirus; Epidemic; Europe; Pneumonia; Quarantine; Transmission
PMID:32322400PMCID:PMC7171182DOI:10.1016/j.nmni.2020.100672
Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view.
Abduljalil JM[SUP]1[/SUP], Abduljalil BM[SUP]2[/SUP].
Author information
Abstract
Since the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, the number of globally confirmed cases according to World Health Organization statistics reached 292 124 in 189 countries by 22 March 2020. The number of deaths reached 12 784, with estimated case-fatality rates ranging from 0.5% to 5.7%. Children population seems to be the least affected by the disease, while the highest rate of death is among the elderly and people with comorbidities. Most infected individuals are asymptomatic or only exhibit mild symptoms. After the incubation period, the most common symptoms are fever, cough and fatigue. Asymptomatic carrier state is of paramount importance because of carriers' ability to spread the infection and to shed the virus into the air and surroundings. Although much is still unknown about SARS-CoV-2, the scientific research is moving at an unprecedented pace towards understanding the nature, effective control, prevention and treatment of SARS-CoV-2. Various reports have suggested an in vivo evolution of the virus, which may explain the rapid spread and changing epidemiology of SARS-CoV-2, but further evidence is needed. Unfortunately, no effective treatment or therapeutic drug is available for the disease; only supportive treatment and classical intervention measures are available for confronting the SARS-CoV-2 pandemic.
? 2020 The Author(s).
KEYWORDS:
2109-nCoV; Asymptomatic; COVID-19; Coronavirus; Epidemic; Europe; Pneumonia; Quarantine; Transmission
PMID:32322400PMCID:PMC7171182DOI:10.1016/j.nmni.2020.100672